SRP230797 PRJNA590711 GSE140736 TIMP-GLIA (gliadin nanoparticle) treatment in transgenic mice expressing celiac disease associated HLA-DQ8 This submission contains raw data obtained from RNA sequencing of mouse spleen cells. Spleen cells were derived from adult female HLA-DQ8, huCD4 transgenic Ab0 NOD mice, treated intravenously either with tolerogenic, immune-modifying nanoparticles containing gliadin (TIMP-GLIA), particles containing irrelevant control ovalbumin (TIMP-OVA), or not receiving treatment. Mice were then immunized with gliadin (except for negative controls), and spleens were collected after 28-30 days. Spleen cells were stimulated with gliadin (or controls) in culture for 72h, and RNA was obtained from cells for transcriptomic studies. Overall design: 2 groups of female HLA-DQ8, huCD4 transgenic Ab0 NOD mice (Jackson Laboratories) were treated i.v. on days -11 and -3 with TIMP-GLIA, or TIMP-OVA, while other groups remained without treatment (2.5mg/dose; n=11-19, 10-12 weeks of age, raised on gluten-free diet AIN-76A). On day 0, mice from the TIMP-GLIA group, the TIMP-OVA group and a control group of mice (IMMU ONLY) were injected at the base of the tail with 100 µg gliadin in complete Freund's adjuvant, followed by 50 µg gliadin in incomplete Freund's adjuvant on day 14. Another control group (NO TREATMENT) remained untreated/non-immunized. On days 28-30, mice were anesthetized with ketamine/xylazine. Spleens were harvested for analyses. The raw data files for each sample in this submission are not de-multiplexed. All sample metadata are included in the file sample_information.xls linked to to the foot of this record. GSE140736 pubmed 32032584